Gilead Sciences

Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company developing and commercializing medicines founded in 1987.

Gilead Sciences is a research-based biopharmaceutical company developing and commercializing medicines that is headquartered in Foster City, California and was founded in 1987. The firm also has locations in La Vernne, California; Oceanside California; San Dimas, California; Miami, Florida; Santa Monica, California; Seattle, Washington; El Segundo, California; and Emeryville, California.

Gilead Sciences specializes in developing and commercializing biopharmaceuticals for HIV/AIDS, liver disease, hematology, oncology, inflammation, respiratory diseases, highly infectious diseases, and viral diseases.

Gilead Sciences actively participates in community partnerships with COMPASS Initiative, Gilead Lift, Gilead HIV Age Positively, TRANScend, and HepConnect.

With the outbreak of COVID-19, Gilead Sciences began evaluating patients and testing remdesivir in 600 patients with moderate COVID-19 symptoms. They also began treatment of 400 patients with severe symptoms. Their results are expected in May.

Investments

Gilead Sciences has made 12 investments, 3 lead investments, and 4 exits. Notable investments made by Gilead Sciences include: Precision BioSciences, Galapagos, Phenex Pharmaceuticals, Allogene Therapeutics, National AIDS Memorial, Tmunity Therapeutics, AlloVir, Goldfinch Biopharma, Lyndra Therapeutics, and Glympse Bio. Gilead has licensed rights to filgotinib, developed by Galapagos, for rheumatoid arthritis and GLPG1690 for idiopathic pulmonary fibrosis, both in late-stage clinical studies.

Timeline

June 29, 2020

Gilead Sciences Inc announces it has set the price its Covid-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries.

Products

Product
Description
Launch date
Industry
Website

An antiviral drug candidate also known as GS-5734 developed by Gilead Sciences to treat Ebola virus that shows potential to treat coronavirus 2019-nCoV.

An immunology drug developed by Galapagos and licensed to Gilead Sciences for the treatment of rheumatoid arthritis

2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

A Deo

Employee

Aaron Arvey

Employee

Aaron Banner

Employee

Abasi Ene-Obong Ph.D.

Employee

Abrar Farooqui

Employee

Aditya Jhanwar

Employee

Adrienne Eng

Employee

Adrienne Orr

Employee

Ahmed Moussa

Employee

Akshith Mithun

Employee

Alan Stowe

Employee

Alex Derchak

Employee

Alex Iserlis

Employee

Alexandria Tong

Employee

Alexej Ladonnikov

Employee

Alexis C Glasgow

Employee

Alison Dowski

Employee

Alison Lin

Employee

Alistair Barkhouse

Employee

Aliyah Sulaiman

Employee

Ambika Gopalan

Employee

Amer Raza

Employee

Amir Abbas

Employee

Amit Vora

Employee

Amrith Mylvara

Employee

Page 1 of 16

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Reuters
July 10, 2020
@bsindia
Gileads remdesivir significantly improved clinical recovery and reduced the risk of death in Covid-19 patients, additional data from a late-stage study showed.
Ankur Banerjee| Reuters
July 10, 2020
@bsindia
The company, which had initially released the data from the trial in April, said the finding requires confirmation in clinical trials
Ben Adams
July 8, 2020
FierceBiotech
Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.
Reuters
July 6, 2020
@bsindia
Mylans version comes after two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, launched their generic versions of the drug
IANS
July 4, 2020
@bsindia
The EU has expedited the authorisation, approving the drug in an exceptionally short timeframe
Ben Adams
June 30, 2020
FierceBiotech
Still flying high from its major biobucks pact with Gilead, kidney disease biotech Goldfinch Bio has followed up with a $100 million funding round.
Chris Ciaccia
June 29, 2020
Fox News
Just days after getting conditional approval for its coronavirus drug remdesivir in Europe, Gilead has announced pricing for the U.S. and other developed countries, charging different rates for the U.S. federal government and private insurers.
Reuters
June 29, 2020
@bsindia
The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to a total of $3,120 per patient
FinSMEs
June 23, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Ben Adams
June 23, 2020
FierceBiotech
As it continues with its small to medium-sized biotech deals, Gilead has put down $275 million for a 49.9% share in immuno-oncology biotech Pionyr with the option to buy it out completely should it pass muster in early clinical tests.
Chris Ciaccia
June 22, 2020
Fox News
Remdesivir, which recently received emergency use approval to treat patients with COVID-19, will be tested in an inhaled version, biotech Gilead Sciences said on Monday.
June 18, 2020
Clinical Trials Arena
Gilead Sciences is set to conduct a Phase II/III trial of its investigational drug remdesivir to treat paediatric patients hospitalised due to Covid-19.
Michele Cohen Marill
June 10, 2020
Wired
PrEP, or pre-exposure prophylaxis, pills are highly effective in blocking HIV if taken daily. But their drug trials have a mixed track record for access.
BioSpace
June 9, 2020
BioSpace
John McHutchison, AO, M.D., Appointed to Board of Directors Adding Significant Industry Experience and Drug Development Expertise
Alex Keown
June 8, 2020
BioSpace
Shares of Gilead Sciences jumped in pre-market trading this weekend following reports that the company has been approached by U.K. pharma giant AstraZeneca regarding a potential merger.
Nick Paul
June 8, 2020
FierceBiotech
Gilead and Galapagos have presented long-term midphase data on filgotinib in patients with active psoriatic arthritis. The analysis shows responses seen at 16 weeks were sustained out to 52 weeks after the initiation of treatment.
BS Web Team
June 8, 2020
@bsindia
Coronavirus vaccine latest update: AstraZeneca has approached Gilead Sciences over a potential merger. It also says it is on track to roll out 2 billion doses of coronavirus vaccines in September
BioSpace
June 5, 2020
BioSpace
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The data from the dou
Alex Keown
June 5, 2020
BioSpace
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Ben Adams
June 4, 2020
FierceBiotech
After swinging the ax on staffers last year and gaining a new CEO a few months back, Five Prime Therapeutics' clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.